Treatment Approach for Declining Testosterone with Osteopenia

Diagnostic Confirmation

The American College of Physicians recommends confirming persistent low testosterone through repeat morning testosterone measurements on two separate occasions, as single measurements are insufficient due to assay variability 1
The European Association of Urology guidelines suggest measuring free testosterone by equilibrium dialysis in addition to total testosterone, especially when total testosterone is borderline 1
Obtaining LH and FSH levels is essential to distinguish primary from secondary hypogonadism, which has critical treatment implications including fertility preservation 1
Documenting baseline hematocrit/hemoglobin before initiating therapy is necessary to monitor for erythrocytosis 1
Measuring baseline PSA if over 40 years old is recommended before starting testosterone therapy 1

The European Association of Urology guidelines favor transdermal preparations over intramuscular injections due to more stable day-to-day testosterone levels 1
The American College of Physicians recommends against testosterone therapy for energy/vitality complaints in age-related low testosterone, but osteopenia may change the risk-benefit calculation 3
Testosterone treatment significantly increases spine bone mineral density in hypogonadal men, according to the European Association of Urology guidelines 1
Hypogonadism is a crucial risk factor for male osteopenia and osteoporosis, contributing to fracture-related morbidity and mortality, as noted by the American College of Physicians 3

The European Association of Urology guidelines recommend checking testosterone levels at 14 days and 28 days after starting treatment or after any dose adjustment 1
Targeting mid-normal testosterone levels (500-600 ng/dL) is recommended by the European Association of Urology guidelines 1
Monitoring hematocrit periodically and withholding treatment if >54% is necessary to prevent erythrocytosis, according to the European Association of Urology guidelines 1
Monitoring PSA levels if over 40 years, with urologic referral if PSA increases >1.0 ng/mL in first 6 months or >0.4 ng/mL per year thereafter, is recommended by the European Association of Urology guidelines 1

If secondary hypogonadism and fertility concerns are present, clomiphene citrate is the preferred alternative, as it stimulates endogenous testosterone production without suppressing spermatogenesis, according to the European Association of Urology guidelines 4
Clomiphene citrate has a lower risk of polycythemia compared to testosterone therapy, but may decrease spine bone mineral density, as noted by the European Association of Urology guidelines 4

Testosterone therapy alone may not fully eliminate hypogonadal osteopenia, and supplemental treatments such as calcium carbonate and anti-osteoporotic agents may be necessary, according to the European Association of Urology guidelines 1
Repeating DXA scanning after 12-24 months of testosterone therapy is recommended to assess response, as noted by the European Association of Urology guidelines 1

Active desire for fertility preservation, active or treated male breast cancer, prostate cancer, hematocrit >54%, and untreated severe obstructive sleep apnea are absolute contraindications to testosterone therapy, according to the European Association of Urology guidelines 1

Testosterone therapy provides small but significant improvements in sexual function and libido, with little to no effect on physical functioning, energy, vitality, or cognition, as noted by the American College of Physicians 3
The primary benefit of testosterone therapy in osteopenia is bone protection and potential improvement in bone mineral density, according to the European Association of Urology guidelines 1